Skip to main content
  • AACR Journals
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Molecular Targets Collections
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Journals
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Molecular Targets Collections
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News

Table of Contents

Highlights

  • Highlights
    Highlights of This Issue
    Mol Cancer Ther July 1 2012 11 (7) 1383-1383;

Spotlight on Clinical Response

  • Spotlight on Clinical Response
    Early FDG/PET Scanning as a Pharmacodynamic Marker of Anti-EGFR Antibody Activity in Colorectal Cancer
    Geoffrey W. Krystal, Erin Alesi and James L. Tatum
    Mol Cancer Ther July 1 2012 11 (7) 1385-1388; DOI:10.1158/1535-7163.MCT-12-0011

Therapeutic Discovery

  • Therapeutic Discovery
    Inducible Silencing of Protein Kinase D3 Inhibits Secretion of Tumor-Promoting Factors in Prostate Cancer
    Courtney R. LaValle, Liyong Zhang, Shuping Xu, Julie L. Eiseman and Q. Jane Wang
    Mol Cancer Ther July 1 2012 11 (7) 1389-1399; DOI:10.1158/1535-7163.MCT-11-0887

  • Therapeutic Discovery
    Human Monoclonal Antibodies Targeting Nonoverlapping Epitopes on Insulin-like Growth Factor II as a Novel Type of Candidate Cancer Therapeutics
    Weizao Chen, Yang Feng, Qi Zhao, Zhongyu Zhu and Dimiter S. Dimitrov
    Mol Cancer Ther July 1 2012 11 (7) 1400-1410; DOI:10.1158/1535-7163.MCT-12-0172

  • Therapeutic Discovery
    ErbB3 Inhibitory Surrobodies Inhibit Tumor Cell Proliferation In Vitro and In Vivo
    Pamela K. Foreman, Medini Gore, Philip A. Kobel, Li Xu, Helena Yee, Charles Hannum, Hoangdung Ho, Sandra M. Wang, Hieu V. Tran, Michael Horowitz, Lawrence Horowitz and Ramesh R. Bhatt
    Mol Cancer Ther July 1 2012 11 (7) 1411-1420; DOI:10.1158/1535-7163.MCT-12-0068

  • Therapeutic Discovery
    Betulinic Acid Targets YY1 and ErbB2 through Cannabinoid Receptor-Dependent Disruption of MicroRNA-27a:ZBTB10 in Breast Cancer
    Xinyi Liu, Indira Jutooru, Ping Lei, KyoungHyun Kim, Syng-ook Lee, Lisa K. Brents, Paul L. Prather and Stephen Safe
    Mol Cancer Ther July 1 2012 11 (7) 1421-1431; DOI:10.1158/1535-7163.MCT-12-0026

  • Therapeutic Discovery
    Adenosine A2A and Beta-2 Adrenergic Receptor Agonists: Novel Selective and Synergistic Multiple Myeloma Targets Discovered through Systematic Combination Screening
    Richard J. Rickles, Winnie F. Tam, Thomas P. Giordano III, Laura T. Pierce, Melissa Farwell, Douglas W. McMillin, Antoaneta Necheva, David Crowe, Mei Chen, William Avery, Vikram Kansra, Steffan T. Nawrocki, Jennifer S. Carew, Francis J. Giles, Constantine S. Mitsiades, Alexis A. Borisy, Kenneth C. Anderson and Margaret S. Lee
    Mol Cancer Ther July 1 2012 11 (7) 1432-1442; DOI:10.1158/1535-7163.MCT-11-0925

  • Therapeutic Discovery
    Inhibition of ATR-Dependent Signaling by Protoapigenone and Its Derivative Sensitizes Cancer Cells to Interstrand Cross-link–Generating Agents In Vitro and In Vivo
    Hui-Chun Wang, Alan Yueh-Luen Lee, Wen-Cheng Chou, Chin-Chung Wu, Chao-Neng Tseng, Kevin Yen-Ting Liu, Wen-Lien Lin, Fang-Rong Chang, Da-Wei Chuang, Attila Hunyadi and Yang-Chang Wu
    Mol Cancer Ther July 1 2012 11 (7) 1443-1453; DOI:10.1158/1535-7163.MCT-11-0921

  • Therapeutic Discovery
    microRNA-9 Targets Matrix Metalloproteinase 14 to Inhibit Invasion, Metastasis, and Angiogenesis of Neuroblastoma Cells
    Huanyu Zhang, Meng Qi, Shiwang Li, Teng Qi, Hong Mei, Kai Huang, Liduan Zheng and Qiangsong Tong
    Mol Cancer Ther July 1 2012 11 (7) 1454-1466; DOI:10.1158/1535-7163.MCT-12-0001

  • Therapeutic Discovery
    Impact of Intrinsic Affinity on Functional Binding and Biological Activity of EGFR Antibodies
    Yu Zhou, Anne-Laure Goenaga, Brian D. Harms, Hao Zou, Jianlong Lou, Fraser Conrad, Gregory P. Adams, Birgit Schoeberl, Ulrik B. Nielsen and James D. Marks
    Mol Cancer Ther July 1 2012 11 (7) 1467-1476; DOI:10.1158/1535-7163.MCT-11-1038

  • Therapeutic Discovery | Free Article
    Engineering and Therapeutic Application of Single-Chain Bivalent TGF-β Family Traps
    John C. Zwaagstra, Traian Sulea, Jason Baardsnes, Anne E.G. Lenferink, Cathy Collins, Christiane Cantin, Béatrice Paul-Roc, Suzanne Grothe, Sazzad Hossain, Louis-Philippe Richer, Denis L'Abbé, Roseanne Tom, Brian Cass, Yves Durocher and Maureen D. O'Connor-McCourt
    Mol Cancer Ther July 1 2012 11 (7) 1477-1487; DOI:10.1158/1535-7163.MCT-12-0060

Preclinical Development

  • Preclinical Development
    Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells
    C. Elizabeth Caldon, C. Marcelo Sergio, Jian Kang, Anita Muthukaruppan, Marijke N. Boersma, Andrew Stone, Jane Barraclough, Christine S. Lee, Michael A. Black, Lance D. Miller, Julia M. Gee, Rob I. Nicholson, Robert L. Sutherland, Cristin G. Print and Elizabeth A. Musgrove
    Mol Cancer Ther July 1 2012 11 (7) 1488-1499; DOI:10.1158/1535-7163.MCT-11-0963

  • Preclinical Development
    Characterization of an Oxaliplatin Sensitivity Predictor in a Preclinical Murine Model of Colorectal Cancer
    Mickey K. Kim, Takuya Osada, William T. Barry, Xiao Yi Yang, Jennifer A. Freedman, Katherine A. Tsamis, Michael Datto, Bryan M. Clary, Timothy Clay, Michael A. Morse, Philip G. Febbo, H. Kim Lyerly and David S. Hsu
    Mol Cancer Ther July 1 2012 11 (7) 1500-1509; DOI:10.1158/1535-7163.MCT-11-0937

  • Preclinical Development
    Modulation of Akt/mTOR Signaling Overcomes Sunitinib Resistance in Renal and Prostate Cancer Cells
    Peter B. Makhov, Konstantin Golovine, Alexander Kutikov, Ervin Teper, Daniel J. Canter, Jay Simhan, Robert G. Uzzo and Vladimir M. Kolenko
    Mol Cancer Ther July 1 2012 11 (7) 1510-1517; DOI:10.1158/1535-7163.MCT-11-0907

  • Preclinical Development
    XIAP Inhibition and Generation of Reactive Oxygen Species Enhances TRAIL Sensitivity in Inflammatory Breast Cancer Cells
    Jennifer L. Allensworth, Katherine M. Aird, Amy J. Aldrich, Ines Batinic-Haberle and Gayathri R. Devi
    Mol Cancer Ther July 1 2012 11 (7) 1518-1527; DOI:10.1158/1535-7163.MCT-11-0787

  • Preclinical Development
    Antitumor Activity of Src Inhibitor Saracatinib (AZD-0530) in Preclinical Models of Biliary Tract Carcinomas
    Giuliana Cavalloni, Caterina Peraldo-Neia, Ivana Sarotto, Loretta Gammaitoni, Giorgia Migliardi, Marco Soster, Serena Marchiò, Massimo Aglietta and Francesco Leone
    Mol Cancer Ther July 1 2012 11 (7) 1528-1538; DOI:10.1158/1535-7163.MCT-11-1020

  • Preclinical Development
    Effect of a Low-Fat Diet Combined with IGF-1 Receptor Blockade on 22Rv1 Prostate Cancer Xenografts
    Ramdev Konijeti, Satomi Koyama, Ashley Gray, R. James Barnard, Jonathan W. Said, Brandon Castor, David Elashoff, Junxiang Wan, Pedro J. Beltran, Frank J. Calzone, Pinchas Cohen, Colette Galet and William J. Aronson
    Mol Cancer Ther July 1 2012 11 (7) 1539-1546; DOI:10.1158/1535-7163.MCT-11-1003

  • Preclinical Development
    Thermal Targeting of an Acid-Sensitive Doxorubicin Conjugate of Elastin-like Polypeptide Enhances the Therapeutic Efficacy Compared with the Parent Compound In Vivo
    Shama Moktan, Eddie Perkins, Felix Kratz and Drazen Raucher
    Mol Cancer Ther July 1 2012 11 (7) 1547-1556; DOI:10.1158/1535-7163.MCT-11-0998

  • Preclinical Development
    Antitumor Action of the MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) in Gastric Cancer Positive for MET Amplification
    Wataru Okamoto, Isamu Okamoto, Tokuzo Arao, Kiyoko Kuwata, Erina Hatashita, Haruka Yamaguchi, Kazuko Sakai, Kazuyoshi Yanagihara, Kazuto Nishio and Kazuhiko Nakagawa
    Mol Cancer Ther July 1 2012 11 (7) 1557-1564; DOI:10.1158/1535-7163.MCT-11-0934

  • Preclinical Development | Free Article
    Preclinical Analysis of the γ-Secretase Inhibitor PF-03084014 in Combination with Glucocorticoids in T-cell Acute Lymphoblastic Leukemia
    Jeremy B. Samon, Mireia Castillo-Martin, Michael Hadler, Alberto Ambesi-Impiobato, Elisabeth Paietta, Janis Racevskis, Peter H. Wiernik, Jacob M. Rowe, John Jakubczak, Sophia Randolph, Carlos Cordon-Cardo and Adolfo A. Ferrando
    Mol Cancer Ther July 1 2012 11 (7) 1565-1575; DOI:10.1158/1535-7163.MCT-11-0938

  • Preclinical Development
    Targeting the Insulin Growth Factor and the Vascular Endothelial Growth Factor Pathways in Ovarian Cancer
    Minghai Shao, Stacy Hollar, Daphne Chambliss, Jordan Schmitt, Robert Emerson, Bhadrani Chelladurai, Susan Perkins, Mircea Ivan and Daniela Matei
    Mol Cancer Ther July 1 2012 11 (7) 1576-1586; DOI:10.1158/1535-7163.MCT-11-0961

  • Preclinical Development
    Smoothened Antagonists Reverse Taxane Resistance in Ovarian Cancer
    Adam D. Steg, Ashwini A. Katre, Kerri S. Bevis, Angela Ziebarth, Zachary C. Dobbin, Monjri M. Shah, Ronald D. Alvarez and Charles N. Landen
    Mol Cancer Ther July 1 2012 11 (7) 1587-1597; DOI:10.1158/1535-7163.MCT-11-1058

  • Preclinical Development
    CDK-4 Inhibitor P276 Sensitizes Pancreatic Cancer Cells to Gemcitabine-Induced Apoptosis
    Dharmalingam Subramaniam, Giridharan Periyasamy, Sivapriya Ponnurangam, Debarshi Chakrabarti, Aravind Sugumar, Muralidhara Padigaru, Scott J. Weir, Arun Balakrishnan, Somesh Sharma and Shrikant Anant
    Mol Cancer Ther July 1 2012 11 (7) 1598-1608; DOI:10.1158/1535-7163.MCT-12-0102

Molecular Medicine in Practice

  • Molecular Medicine in Practice
    The Association of PI3 Kinase Signaling and Chemoresistance in Advanced Ovarian Cancer
    Craig P. Carden, Adam Stewart, Parames Thavasu, Emma Kipps, Lorna Pope, Mateus Crespo, Susana Miranda, Gerhardt Attard, Michelle D. Garrett, Paul A. Clarke, Paul Workman, Johann S. de Bono, Martin Gore, Stan B Kaye and Udai Banerji
    Mol Cancer Ther July 1 2012 11 (7) 1609-1617; DOI:10.1158/1535-7163.MCT-11-0996

Back to top
PreviousNext
Molecular Cancer Therapeutics: 11 (7)
July 2012
Volume 11, Issue 7
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by Author

Sign up for alerts

Issue Highlights

  • Engineering and Therapeutic Application of Single-Chain Bivalent TGF-β Family Traps
  • Preclinical Analysis of the γ-Secretase Inhibitor PF-03084014 in Combination with Glucocorticoids in T-cell Acute Lymphoblastic Leukemia
  • Effect of a Low-Fat Diet Combined with IGF-1 Receptor Blockade on 22Rv1 Prostate Cancer Xenografts
  • Smoothened Antagonists Reverse Taxane Resistance in Ovarian Cancer
  • The Association of PI3 Kinase Signaling and Chemoresistance in Advanced Ovarian Cancer

Jump to

  • Highlights
  • Spotlight on Clinical Response
  • Therapeutic Discovery
  • Preclinical Development
  • Molecular Medicine in Practice
Advertisement
  • Most Cited
  • Most Read
Loading
  • Site-specific PBD ADCs with Immolating Disulfide Linkers
  • Synergistic Cytoskeletal Inhibitors
  • Wnt Signaling Inhibition Promotes Apoptosis in Sarcomas
  • Combination of BET and BCL2 Inhibitors in SCLC
  • CTNNB1-Mutant Status Predicts TTK Inhibitor Sensitivity
More...
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright 2016 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement